Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus on both top and bottom lines: revenue was $1.71M vs. $0.93M expected, while GAAP EPS was -$0.04 vs. -$0.05 expected. The revenue outperformance was driven by a collaboration agreement with Chugai, while the net loss narrowed YoY to $8.4M. With a recently completed $20M offering and $53.4M in cash, management's guidance suggests a runway through 2027, supporting upcoming Phase 1b obesity trials by late 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Rani Therapeutics(RANI) the Revenue is 1.708 M (--%), Beat estimate;the EBIT is -8.828 M (+15.96%), Beat estimate;the EPS is -0.04 (+77.78%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.01B15.96%
-0.01B8.09%
+0.00B7.87%
EPSExceed expectations
-0.0477.78%
-0.0572.22%
+0.01005.56%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf